Fund+ | Activity | F4

Team Portfolio Raise Champions Essays

F4/Fund+/Activity

Fund+ Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

Milestone

Portfolio company Ona Therapeutics advanced its ONA-255 Phase 1a trial and appointed Aleix Prat, MD, PhD as Chief Medical Officer.

Ona Therapeutics

Ona Therapeutics Fund+

fundplus.beSEP 24, 2026

SEP 24, 2026

Investment

Participated in Novadip Biosciences' EUR 10.4M convertible financing round led by New Science Ventures, bringing total convertible financing to EUR 20M.

Novadip

fundplus.beSEP 21, 2026

SEP 21, 2026

Investment

Participated in Ona Therapeutics' oversubscribed $86.6M Series B financing co-led by Columbus Venture Partners and Merieux Equity Partners.

Ona Therapeutics

Ona Therapeutics Fund+

fundplus.beJUN 4, 2026

JUN 4, 2026